Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Lenalidomide in Relapsed/Refractory Multiple Myeloma
NCT03333746Phase 2Terminated
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in multiple myeloma (MM). Started Mar 2018; status: terminated.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03333746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333746.